Ferric Derisomaltose PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
~150000 g/mol
Drug class
Intravenous ferric iron–carbohydrate complexparenteral iron replacement agent
Mechanism of action
A stable iron(III)-hydroxide complex with derisomaltose carbohydrate. After intravenous administration, iron is taken up by reticuloendothelial cells and released for transferrin binding, haemoglobin synthesis and replenishment of iron stores; it is not a simple iron salt.
Indications / reported uses
Treatment of iron-deficiency anaemia in adults who have intolerance to oral iron or have had an unsatisfactory response to oral iron
Use in adults with non-dialysis-dependent chronic kidney disease or other specified causes of iron deficiency according to the product label
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Ferric Derisomaltose PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ferric Derisomaltose Permitted Daily Exposure (PDE) report (the Ferric Derisomaltose PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ferric Derisomaltose Occupational Exposure Limit (OEL) report (the Ferric Derisomaltose OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.